Trial Profile
Multicenter Non-Comparative Expanded Access Program of to Assess Safety of Rituximab (Mab Anti Cd-20) in Patients With Rheumatoid Arthritis (Ser)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 17 Aug 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2009 Planned end date changed from 1 Jul 2009 to 1 Sep 2010as reported by ClinicalTrials.gov.